re Atryn price in Europe, 3 separate observations/ musings
* Am not an expert in blood products, but it appears to me that in order to support this price level, Leo would have needed a value dossier which highlights the savings which Atryn leads to compared to the plasma-derived substance from a hospital perspective, i.e. you need to show that the drug leads to a shorter hospital length of stay, or savings in personnel time, materials used, improvement in hospital processes etc. If you cannot show this directly, I think it becomes very difficult to justify a premium price.
* To the best of my knowledge, in Germany, a very important European market in terms of size and price level (for reference pricing), Antithrombin III ("plasma-based and that produced by gene-technology")is reimbursed in the DRG 2008 system with a special fee in addition to whatever DRG a patient has ("Zusatzentgelt" , code ZE47), which I think is the same all over the country which gives a specific price ceiling for all kinds of defined dosages up to which the hospital will be reimbursed for the use of the product, e.g. 10'000-14'999 IE is reimbursed with max €991.67. How does this compare to the UK price?
*Hospital purchasing departments/ pharmacies don't appear to care very much about money saved from another budget but their own (avoided blood borne infections), in addition, I am not aware of a lot of studies putting an evidence-based and credible dollar/ euro amount on the potential savings associated with that.
Market Data 
Markets 
AI
